Key Takeaways
- • Expedition Therapeutics closed an oversubscribed $115 million Series B financing round led by General Atlantic, with participation from institutional investors including RA Capital, Vivo Capital, and KKR's Dawn Biopharma platform.
- • The company is a clinical-stage biotechnology firm focused on developing novel oral small molecule therapies targeting inflammatory and respiratory diseases.
- • The round attracted both venture capital and alternative asset managers, including hedge fund participation from Adage Capital Management and Balyasny Asset Management, signaling institutional confidence in the clinical pipeline.
- • Existing investors Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners also participated in the oversubscribed round, demonstrating strong investor retention and follow-on commitment.
Summary
Expedition Therapeutics announced the closing of an oversubscribed $115 million Series B financing round on August 10, 2026, establishing a diversified investor syndicate spanning venture capital, growth equity, and alternative asset management firms. The round was led by General Atlantic, a prominent global investor with significant biotechnology exposure, and included strategic participation from RA Capital and Vivo Capital alongside financial investors from the hedge fund and asset management space.
The company's clinical-stage focus on oral small molecule therapies for inflammatory and respiratory disease indications attracted a broad institutional investor base. The financing syndicate included notable returns from existing backers—Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners—alongside new institutional capital from Adage Capital Management and Balyasny Asset Management. KKR's Dawn Biopharma platform and Logos Capital also participated, reflecting confidence in the company's therapeutic approach and commercial potential.
The oversubscribed status of the round suggests demand exceeded available allocation, a positive signal for investor appetite in the clinical-stage biotech sector, particularly in the oral small molecule space where manufacturing and bioavailability advantages can drive competitive differentiation. The participation of alternative investors alongside traditional venture and growth equity players indicates the financing may have attracted capital from multi-strategy and hedge fund allocators diversifying into life sciences venture exposure.
The company's clinical-stage focus on oral small molecule therapies for inflammatory and respiratory disease indications attracted a broad institutional investor base. The financing syndicate included notable returns from existing backers—Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners—alongside new institutional capital from Adage Capital Management and Balyasny Asset Management. KKR's Dawn Biopharma platform and Logos Capital also participated, reflecting confidence in the company's therapeutic approach and commercial potential.
The oversubscribed status of the round suggests demand exceeded available allocation, a positive signal for investor appetite in the clinical-stage biotech sector, particularly in the oral small molecule space where manufacturing and bioavailability advantages can drive competitive differentiation. The participation of alternative investors alongside traditional venture and growth equity players indicates the financing may have attracted capital from multi-strategy and hedge fund allocators diversifying into life sciences venture exposure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.